Register for this series here:

 https://www2.gotomeeting.com/register/597910794

ABOUT THIS WEBINAR

Rich Bendis and Dr. Mark Rohrbaugh will discuss a new Entrepreneur-in-Residence (EIR) program financed by BioHealth Innovation (BHI) which places a full-time, experienced, serial entrepreneur inside the National Institutes of Health (NIH), Office of Technology Transfer. This EIR is designed to be an active partner with research institutions to source, fund, and grow high-potential, early-stage products through project-focused companies. The entrepreneurs in the program support the formation of new companies based upon innovative discoveries in the areas of drugs, vaccines, therapeutics, diagnostics, and medical devices from the intramural research programs at the NIH and Food and Drug Administration (FDA), as well as from universities and businesses. The EIR will find, evaluate, and support the development of new start-up companies based upon technology license agreements from technology transfer offices or equivalent units within the research institutions.

BHI, a new regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced on March 26, 2012 its selection of Todd Chappell as the first Entrepreneur-in-Residence (EIR) for BHI at the National Institutes of Health (NIH) Office of Technology Transfer (OTT). Mr. Chappell, a venture capital-backed entrepreneurial leader and inventor with more than ten years of experience in molecular biology research, drug development and life sciences business strategy, will help support the development of new start-up companies based upon OTT technology license agreements. As the first EIR, Mr. Chappell – who will have dual responsibility to both BHI and NIH – will assist OTT in the evaluation of existing technologies, provide an entrepreneurial perspective to OTT in its evaluation of new licensing proposals from start-up companies, advise OTT on opportunities for new ventures based on NIH/Food & Drug Administration (FDA) technologies, assist with developmental strategies, and mentor scientists to help ensure their research becomes commercially valuable.

ABOUT THE PRESENTERS:

Mr. Bendis is a distinguished and successful entrepreneur, corporate executive, venture capitalist, investment banker, innovation based economic development (IBED) leader, international speaker and consultant in Innovation and Economy Building. He currently serves as the founding President and CEO of Innovation America (IA), a Global Innovation Intermediary focused on accelerating the growth of the entrepreneurial innovation economy in America.He is also serving as the interim CEO for BioHealth Innovation inc., a Central Maryland innovation intermediary.

Mr. Bendis is also serving as the interim CEO of BioHealth Innovation inc, a Rockville, Maryland based private/public partnership and innovation intermediary, focused on commercializing the BioHealth innovations from Federal Labs, Universities, Industry spinouts and Entrepreneurs in the region.

Mr. Bendis has been appointed to several national innovation related organizations and committees include the White House U.S. Innovation Partnership (USIP) Advisory Task Force and Co-Chair of the Small Business Innovation Research Committee), the National Governor’s Association (NGA) Science and Technology Council of the State’s Executive Committee, the State Federal Technology Task Force, the National Academies (NAS) committee on “Competing in the 21st Century: Best Practices in State and Regional Innovation Initiatives”; National Academies National Research Review of “an Assessment of the SBIR Program; National Institute of Standards and Technology Manufacturing Extension Partnership (MEP) National Advisory Board; U.S. Small Business Administration’s Angel Capital Electronic Network (ACENET) Board of Directors; American Academy for the Advancement of Science (AAAS) Nominating Committee and the American Association Research Competitiveness Program Advisory Committee; Council on Competitiveness – Clusters of Innovation Committee.

Mr. Bendis is currently or has previously served as a board member and representative to the following organizations: National Association of State Venture Funds (NASVF) Founding Board member and Vice Chairman of the Executive Committee; State Science and Technology Institute (SSTI) Founding Board member: Eisenhower Fellowships Nominating Committee, the Ernst and Young Entrepreneurial Institute Member and as a past EOY winner as well as a national/regional Judge, Advisory Board member of the Technopolicy Network.

Mr. Bendis has provided global consulting services to over 18 countries and 24 states, several cities and regions, along with international organizations including the United Nations, NATO, UK Trade and Industry, European Commission, French Embassy, the German Marshall Fund, The Canadian Consulate, COTEC, TechnoPolicy, Science Works, METI, AKEA, the International Science Parks and Innovation Expert Group and other global entities. Mr. Bendis is an International speaker, focusing on Innovation , Entrepreneurship, and Developing and implementing Innovation Based Economic Development Strategies.

Mr. Bendis founded the Bendis Investment Group LLC, (BIG), a financial intermediary and consulting firm, along with managing his own angel investment portfolio. Mr. Bendis also founded and served as the founding President and CEO of Innovation Philadelphia (IP), a three state regional public/private partnership dedicated to growing the wealth and workforce of the Greater Philadelphia Region. IP managed a portfolio of programs in four distinct areas: Direct Equity Investment/Financing Assistance; Technology Commercialization; Global/Regional Economic and Workforce Development; and Market Research and Branding. Mr. Bendis currently serves as the Chairman of the innovation Philadelphia, Board of Directors.

Previously, Mr. Bendis successfully leveraged a career in the private sector (with Quaker Oats, Polaroid, Texas Instruments, Marion Laboratories and Kimberly Services) and the venture capital industry (RAB Ventures) to lead the Kansas Technology Enterprise Corporation (KTEC). As its president and CEO, he developed KTEC into a globally recognized model for technology-based economic development. Mr. Bendis also successfully built an Inc. 500 healthcare software company, Continental Healthcare Systems, Inc., which he took public on NASDAQ and later sold to an international conglomerate. He was a nominee for the 2005 Ernst and Young National Entrepreneur Supporter of the Year Award (EOY) and was the 1996 recipient of the Regional Ernst and Young Entrepreneur of the Year Award.

Mark L. Rohrbaugh, Ph.D., J.D. serves as the Director, Office of Technology Transfer (OTT), National Institutes of Health (NIH), Department of Health and Human Services (HHS). OTT manages the patenting and commercial licensing of NIH and FDA intramural inventions and serves as the lead office within the HHS for the development of technology transfer policy. The OTT portfolio is the largest biomedical patent and license portfolio among public sector institutions. Companies marketing hundreds of products under OTT licenses report annual sales approaching $6B annually. 26 FDA approved products have been brought to market, and 70 products are in private sector clinical trials.

Mark serves on the National Science and Technology Council Technology Committee and the HHS Innovation Council and is Vice-Chair of the Public Health Service Technology Transfer Policy Board. He has advised the NIH and HHS on a wide range of intellectual property issues including those involving stem cell research, pandemic influenza, access to products in developing countries, and gene diagnostic technologies. He has represented the HHS at the Organization for Economic Cooperation and Development (OECD) and the World Health Organization (WHO).

Mark previously served as the Director, Office of Technology Development, National Institute of Allergy and Infectious Diseases (NIAID). Prior to joining the NIH, he conducted molecular and cell biology research at the University of Minnesota and two start-up companies. He received his Ph.D. in biochemistry from The Pennsylvania State University and a degree in law from The George Washington University Law School.

IMPORTANT INFORMATION FOR ATTENDEES:

WEBINAR DURATION: Each session is a 30-minute webinar with 15 minutes of presentation and 15 minutes of Q&A.

COST: Free, but registration required by clicking on register the Register button above.

HOW TO PARTICIPATE?: This webinar is online. You need a computer with web access for the visual/audio. You may also dial-in using the audio-only telephone number. The call in details and instructions on how to join the webinar will be sent to you via email after you register. Once registered to the webinar you will receive a reminder email 24 hours before the start of the webinar with instructions on how to join.

QUESTIONS TO SPEAKERS: Q&A is conducted by a chat box to the speakers.

WHO SHOULD PARTICIPATE IN THE WEBINAR?: National and international media, federal and state government officials, venture capitalists, angel investors, Global 1000 companies, industry representatives, university officials, entrepreneurs and individual investors.

SLIDES AND VIDEO: The slide presentations and video recording will be available on this page. If you are unable to join the live webinar, you may view the recorded video that will be posted within 24 hours after the scheduled webinar ends.